mirrors Bax/Bak double deficiency and argue that this provides proof for the 'direct activation' model. This is, however, incorrect. First, there are substantial differences in phenotype between Bim/Bid/Puma TKO 1 and Bax/Bak DKO mice. 2 Although Bax/Bak DKO mice die perinatally with severe brain abnormalities, no such profound neurological defects and associated perinatal lethality were reported for the Bim/Bid/Puma TKO mice. Furthermore, although some interdigital webbing persisted in Bim/Bid/Puma TKO mice, 1 it appears less extensive than in Bax/Bak DKO mice 2 or in Bim À/À Bmf À/À mice 6 (AV, PB and VL, unpublished), in which webs persist despite the presence of both Bid and Puma. Moreover, the defect in vaginal development in Bim/Bid/Puma TKO mice shows incomplete penetrance, 1 but occurs in 100% of Bax/Bak DKO mice. 2 Thus, in a significant portion of Bim/Bid/Puma TKO mice, the physiological cell death driven by Bax and/or Bak continues to some extent in multiple tissues.
The reported in vitro cell survival assays also fail to unambiguously demonstrate that all induction of apoptosis requires Bid, Bim or Puma. A proportion of the TKO lymphoid cells still died in response to DNA damage or glucocorticoids, 1 whereas Bax/Bak DKO cells are fully refractory. 2 This difference may indicate that these death stimuli activate additional (i.e., non 'direct activator') BH3-only proteins that collectively can neutralize the prosurvival Bcl-2 proteins in these cells, thereby leading to Bax/Bak activation, consistent with the 'indirect model'. Moreover, the role of Bid in the lymphocyte death probably is negligible: although this study failed to provide data on survival of Bim/Puma DKO lymphocytes, previous studies 7, 8 have shown that their combined loss renders multiple hematopoietic cell types as resistant to the apoptotic stimuli studied as reported for the Bim/Bid/Puma TKO cells. 1 Thus, the phenotype of the TKO mice is less profound than that of Bax/Bak DKO animals and does not prove the direct activation model. As the TKO mice lack the three BH3-only proteins that can neutralize all the prosurvival family members, 5 the observed apoptotic deficiencies are also compatible with the 'indirect model'. Nevertheless, increasing in vitro findings, for example, 9, 10 suggest that certain BH3 domains can directly activate Bax, and a recent in vivo study using gene-targeted mice in which the BH3 region of Bim has been subtly altered argues that aspects of both models may well hold. 11 Most of the seemingly conflicting published results can be reconciled if Bax and Bak can be activated in multiple ways: in some circumstances by Bid, Bim or Puma, but also, albeit perhaps less efficiently, by certain other BH3-only proteins, 12 or by mechanisms independent of BH3-only proteins, 3 such as by Bax phosphorylation, heatinduced conformational change, or spontaneous activation after the neutralization or degradation of the restraining prosurvival Bcl-2 proteins, as seen in platelets. As small molecules that target prosurvival Bcl-2 proteins are showing great clinical promise, it will be essential to understand these mechanisms to achieve optimal killing of tumor cells.
